736 related articles for article (PubMed ID: 25580570)
1. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline.
Gault VA; Lennox R; Flatt PR
Diabetes Obes Metab; 2015 Apr; 17(4):403-13. PubMed ID: 25580570
[TBL] [Abstract][Full Text] [Related]
2. DPP-4 inhibitors improve cognition and brain mitochondrial function of insulin-resistant rats.
Pintana H; Apaijai N; Chattipakorn N; Chattipakorn SC
J Endocrinol; 2013 Jul; 218(1):1-11. PubMed ID: 23591914
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the independent and combined effects of sub-chronic therapy with metformin and a stable GLP-1 receptor agonist on cognitive function, hippocampal synaptic plasticity and metabolic control in high-fat fed mice.
Lennox R; Porter DW; Flatt PR; Holscher C; Irwin N; Gault VA
Neuropharmacology; 2014 Nov; 86():22-30. PubMed ID: 24998752
[TBL] [Abstract][Full Text] [Related]
4. Stable oxyntomodulin analogues exert positive effects on hippocampal neurogenesis and gene expression as well as improving glucose homeostasis in high fat fed mice.
Pathak NM; Pathak V; Lynch AM; Irwin N; Gault VA; Flatt PR
Mol Cell Endocrinol; 2015 Sep; 412():95-103. PubMed ID: 26048772
[TBL] [Abstract][Full Text] [Related]
5. (Val(8))GLP-1-Glu-PAL: a GLP-1 agonist that improves hippocampal neurogenesis, glucose homeostasis, and β-cell function in high-fat-fed mice.
Lennox R; Porter DW; Flatt PR; Gault VA
ChemMedChem; 2013 Apr; 8(4):595-602. PubMed ID: 23138973
[TBL] [Abstract][Full Text] [Related]
6. Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice.
Waget A; Cabou C; Masseboeuf M; Cattan P; Armanet M; Karaca M; Castel J; Garret C; Payros G; Maida A; Sulpice T; Holst JJ; Drucker DJ; Magnan C; Burcelin R
Endocrinology; 2011 Aug; 152(8):3018-29. PubMed ID: 21673098
[TBL] [Abstract][Full Text] [Related]
7. FGF21 and DPP-4 inhibitor equally prevents cognitive decline in obese rats.
Sa-Nguanmoo P; Tanajak P; Kerdphoo S; Jaiwongkam T; Wang X; Liang G; Li X; Jiang C; Pratchayasakul W; Chattipakorn N; Chattipakorn SC
Biomed Pharmacother; 2018 Jan; 97():1663-1672. PubMed ID: 29793329
[TBL] [Abstract][Full Text] [Related]
8. Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat fed mice.
Lamont BJ; Drucker DJ
Diabetes; 2008 Jan; 57(1):190-8. PubMed ID: 17928394
[TBL] [Abstract][Full Text] [Related]
9. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
Herman GA; Bergman A; Stevens C; Kotey P; Yi B; Zhao P; Dietrich B; Golor G; Schrodter A; Keymeulen B; Lasseter KC; Kipnes MS; Snyder K; Hilliard D; Tanen M; Cilissen C; De Smet M; de Lepeleire I; Van Dyck K; Wang AQ; Zeng W; Davies MJ; Tanaka W; Holst JJ; Deacon CF; Gottesdiener KM; Wagner JA
J Clin Endocrinol Metab; 2006 Nov; 91(11):4612-9. PubMed ID: 16912128
[TBL] [Abstract][Full Text] [Related]
10. Dipeptidyl peptidase-4 inhibitor decreases abdominal aortic aneurysm formation through GLP-1-dependent monocytic activity in mice.
Lu HY; Huang CY; Shih CM; Chang WH; Tsai CS; Lin FY; Shih CC
PLoS One; 2015; 10(4):e0121077. PubMed ID: 25876091
[TBL] [Abstract][Full Text] [Related]
11. Positive interplay between FFAR4/GPR120, DPP-IV inhibition and GLP-1 in beta cell proliferation and glucose homeostasis in obese high fat fed mice.
Owolabi AI; Corbett RC; Flatt PR; McKillop AM
Peptides; 2024 Jul; 177():171218. PubMed ID: 38621590
[TBL] [Abstract][Full Text] [Related]
12. Sustained high-fat diet modulates inflammation, insulin signalling and cognition in mice and a modified xenin peptide ameliorates neuropathology in a chronic high-fat model.
Denver P; Gault VA; McClean PL
Diabetes Obes Metab; 2018 May; 20(5):1166-1175. PubMed ID: 29316242
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic effects of the dipeptidyl peptidase-IV inhibitor, sitagliptin, on non-alcoholic steatohepatitis in FLS-ob/ob male mice.
Onoyama T; Koda M; Okamoto T; Kishina M; Matono T; Sugihara T; Murawaki Y
Mol Med Rep; 2015 Nov; 12(5):6895-902. PubMed ID: 26397061
[TBL] [Abstract][Full Text] [Related]
14. The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates High-fat Induced Cognitive Decline in Tauopathy Model Mice.
Nakaoku Y; Saito S; Yamamoto Y; Maki T; Takahashi R; Ihara M
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126115
[TBL] [Abstract][Full Text] [Related]
15. Novel dual incretin agonist peptide with antidiabetic and neuroprotective potential.
Pathak NM; Pathak V; Gault VA; McClean S; Irwin N; Flatt PR
Biochem Pharmacol; 2018 Sep; 155():264-274. PubMed ID: 30028989
[TBL] [Abstract][Full Text] [Related]
16. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, attenuates apoptosis of vascular smooth muscle cells and reduces atherosclerosis in diabetic apolipoprotein E-deficient mice.
Li B; Luo YR; Zhang Q; Fu SH; Chen YD; Tian JW; Guo Y
Vascul Pharmacol; 2021 Oct; 140():106854. PubMed ID: 33781961
[TBL] [Abstract][Full Text] [Related]
17. Divergent effects of liraglutide, exendin-4, and sitagliptin on beta-cell mass and indicators of pancreatitis in a mouse model of hyperglycaemia.
Mondragon A; Davidsson D; Kyriakoudi S; Bertling A; Gomes-Faria R; Cohen P; Rothery S; Chabosseau P; Rutter GA; da Silva Xavier G
PLoS One; 2014; 9(8):e104873. PubMed ID: 25119717
[TBL] [Abstract][Full Text] [Related]
18. Short and Long Term Effects of a DPP-4 Inhibitor Versus Bedtime NPH Insulin as ADD-ON Therapy in Patients with Type 2 Diabetes.
da Silva GM; Nogueira KC; Fukui RT; Correia MR; Dos Santos RF; da Silva ME
Curr Pharm Des; 2016; 22(44):6716-6721. PubMed ID: 27928958
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
20. A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice.
Matsubara J; Sugiyama S; Sugamura K; Nakamura T; Fujiwara Y; Akiyama E; Kurokawa H; Nozaki T; Ohba K; Konishi M; Maeda H; Izumiya Y; Kaikita K; Sumida H; Jinnouchi H; Matsui K; Kim-Mitsuyama S; Takeya M; Ogawa H
J Am Coll Cardiol; 2012 Jan; 59(3):265-76. PubMed ID: 22240132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
